Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Ocrelizumab [USAN:INN:JAN]
RN: 637334-45-3
UNII: A10SJL62JY

Note

  • An anti-CD20 antibody for treatment of autoimmune disease and cancer.

    NCI: A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning. (NCI Thesaurus)

Molecular Formula

  • Unspecified
 

Classification Code

  • Treatment of Rheumatoid Arthritis

Names and Synonyms

Name of Substance

  • Monoclonal antibody PRO70769
  • Ocrelizumab [USAN:INN:JAN]

Synonyms

  • Ocrelizumab
  • Ocrevus
  • PR070769
  • PRO-70769
  • PRO70769
  • R-1594
  • rhuMAb 2H7
  • UNII-A10SJL62JY

Registry Numbers

CAS Registry Number

  • 637334-45-3

FDA UNII

  • A10SJL62JY

System Generated Number

  • 0637334453